Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on August 14 a mix of intellectual property and manufacturing progress for its lead radiotherapy candidate Actimab-A, alongside a separate and more consequential disclosure: NYSE Regulation has accepted the company’s plan to regain compliance with the exchange’s continued listing standards, after confirming Actinium is not currently meeting two of them. The two pieces of news matter differently to investors, and this article treats them separately rather than letting the patent updates overshadow the listing issue.

What Actimab-A Is

Actimab-A is a radiotherapy that links a cell-targeting antibody to a radioactive isotope, delivering radiation directly to cancer cells rather than through external radiation or traditional chemotherapy; it targets CD33, a marker found on cells involved in blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Over the past twelve months, Actinium says it has expanded the patent estate covering Actimab-A across four separate areas. Two new U.S. patents, US 12,491,274 covering sarcoma treatment and US 12,539,340 covering solid tumors generally (alone or combined with checkpoint therapy), extend the platform beyond blood cancers into solid tumors by targeting immune-suppressing cells within tumors rather than the tumors themselves; those patents run through October 2043, with related applications still pending in the U.S., Canada, and Europe. Separate patents and applications cover Actimab-A’s use in AML patients with low peripheral blast counts (US 12,410,249, protected through 2039), in combination with the drug venetoclax, and in combination with a chemotherapy regimen called CLAG-M, with issued or pending counterparts across the U.S., Canada, Japan, Europe, Mexico, and China.

Manufacturing Update

On manufacturing, Actinium has amended its Investigational New Drug (IND) application to add a second manufacturer for Actimab-A. That additional manufacturer will supply both studies conducted under the company’s Cooperative Research and Development Agreement with the National Cancer Institute and separate company-sponsored studies, which Actinium says carry clinical milestones expected across the second half of 2026 and into 2027. Adding manufacturing capacity ahead of a broader slate of studies is a supply-chain and operational move rather than a new efficacy claim, and it does not by itself change what is known about how well Actimab-A works.

The NYSE American Listing Deficiency

The more significant disclosure for investors is the second half of the release. Actinium confirmed it is not currently in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, the exchange’s continued listing standards. In plain terms, based on how NYSE American has described these same standards in other companies’ public filings, Section 1003(a)(ii) requires a listed company to hold stockholders’ equity of at least $4 million if it has reported losses in three of its last four fiscal years, while Section 1003(a)(iii) raises that threshold to $6 million if the company has reported losses in each of its last five fiscal years. Actinium’s release does not restate its specific stockholders’ equity figure here, but non-compliance with both sections together implies the company’s equity cushion has fallen below the higher of those two thresholds while it has been posting losses in every recent fiscal year, which is consistent with a small, clinical-stage biotech still working toward approved products rather than evidence of an immediate operational crisis.

The Compliance Plan

NYSE Regulation accepted the compliance plan Actinium submitted on June 18, 2026, and granted a plan period running through November 27, 2027, which the company describes as the maximum extension available under Section 1009 of the Company Guide. Actinium’s stock continues trading on NYSE American under the ticker ATNM throughout this period, provided the company keeps meeting the terms of its plan and the exchange’s other continued listing requirements; NYSE Regulation staff will review Actinium’s progress against the plan periodically rather than simply waiting until the deadline. Getting the maximum allowable extension is a favorable outcome relative to the alternative of a shorter timeline or delisting, but it does not resolve the underlying equity and profitability issues that triggered the deficiency in the first place.

The Broader Pipeline

Actinium describes a broader pipeline beyond Actimab-A, including ATNM-400, a solid-tumor radiotherapy candidate targeting a different antigen than PSMA with preclinical activity reported in prostate, lung, and breast cancer models, and two conditioning agents, Iomab-B and Iomab-ACT, used to prepare patients for bone marrow or cell and gene therapy. The company says it holds roughly 250 patents and patent applications in total, including intellectual property related to producing the isotope actinium-225 using a cyclotron, a radioactive material that is itself in limited global supply and is often cited as a bottleneck for the broader alpha-emitter radiotherapy field. None of these broader pipeline assets were the subject of new data in this release, and the company’s own description of Actimab-A’s survival benefit in combination with CLAG-M is a company characterization rather than new data presented here.

What’s Next

This article covers a mix of intellectual property, manufacturing, and stock-exchange compliance disclosures and is not an investment recommendation.

Sources

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update, PRNewswire, August 14, 2026.

Azitra, Inc. (SEC Form 10-Q): disclosure explaining NYSE American Company Guide Sections 1003(a)(ii) and 1003(a)(iii), cited for background on the continued listing standards referenced in the release.

Editorial Disclosure

This article is based on a press release issued by Actinium Pharmaceuticals, Inc. on August 14, 2026, distributed via PRNewswire, with background on NYSE American Company Guide Sections 1003(a)(ii) and 1003(a)(iii) drawn from another issuer’s public SEC filing describing the same standards, cited above. Actinium Pharmaceuticals trades on NYSE American under the ticker ATNM. BioTech Stocks Daily was not compensated for this coverage. Statements regarding patent scope, enforceability, clinical milestone timing, and the company’s ability to regain compliance with NYSE American listing standards are forward-looking and involve risks and uncertainties; actual results may differ materially. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.